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Abstract  16 
 17 
Cancer cells tend to metastasize first to tumor-draining lymph nodes (LN), but the 18 
mechanisms mediating cancer cell invasion into the lymphatic vasculature remain little 19 
understood. Here we show that in the human breast tumor microenvironment (TME) the 20 
presence of increased numbers of RORγt+ group 3 innate lymphoid cells (ILC3) correlates 21 
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with an increased likelihood of LN metastasis. In a preclinical mouse model of breast cancer, 1 
CCL21-mediated recruitment of ILC3 to tumors stimulated the production of the CXCL13 by 2 
TME stromal cells, which in turn promoted ILC3-stromal interactions and production of the 3 
cancer cell motile factor RANKL. Depleting ILC3 or neutralizing CCL21, CXCL13 or 4 
RANKL was sufficient to decrease LN metastasis. Our findings establish a role for 5 
RORγt+ILC3 in promoting lymphatic metastasis by modulating the local chemokine milieu 6 
of cancer cells in the TME.  7 
 8 
Introduction 9 
Breast cancer is the most common malignant neoplasm with significant morbidity and 10 
mortality. The ability of cancer cells to invade lymphatics stratifies breast cancers into 11 
distinct prognostic groups (1). The molecular mechanisms mediating this tumor cell entry 12 
remain unclear but studies have established important roles for the lymphoid chemokines 13 
CXCL13, CCL19 and CCL21 (2). 14 
An important early step in the construction of lymphoid organs is the recruitment of 15 
lymphoid tissue inducer cells (LTis) by CXCL13 and CCL21, which are recognized via the 16 
receptors CXCR5 and CCR7, respectively (3-5). LTis are members of the innate lymphoid 17 
cells (ILCs) family. Recent moves to propose a uniform nomenclature divide these cells into 18 
three groups (6), and  LTis represent the prototypic cell type of the “group 3” RORγt+ family 19 
of ILCs.   We will refer to these cells henceforth as ILC3. ILC3 play a major role in lymphoid 20 
tissue development both in the embryo (7) and in adult life (8, 9). Within the secondary 21 
lymphoid structures, ILC3 produce lymphotoxin (LT)α1β2 which binds LTβR on 22 
mesenchymal stromal cells (MSC), stimulating the production of CXCL13, CCL19 and 23 
CCL21, as well as the tumor necrosis factor (TNF)-family member, RANKL;  promoting 24 
lymphocyte recruitment and compartmentalization (10).  25 
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The presence or role of these cells has not yet been explored in breast cancers. Here we 1 
demonstrate that CCL21-dependent recruitment of ILC3s into mammary tumors results in a 2 
CXCL13-dependent positive feedback loop between ILC3 and MSCs. Antibody blocking 3 
experiments in BALB/c and Rag1-/- mice demonstrated that CCL21, CXCL13, ILC3 and 4 
RANKL all promote metastasis to the LN. We report the novel identification of 5 
RORγt+ILC3s within the human TME, their association with more agressive breast cancer 6 
subtypes, and lymphatic metastasis.  7 
 8 
Methods & Materials 9 
 10 
Human tissue: Tissue samples and data from patients were obtained from The King’s Health 11 
Partners (KHP) Cancer Biobank at Guy’s Hospital, London (REC No: 07/40874/131). 12 
Mice: Experiments were performed in accordance with the UK Home Office Animals 13 
Scientific Procedures Act, 1986 and the UKCCCR guidelines. Tumors were established by 14 
injection of 4T1.2 cells into the mammary fat pad of 6–8-week old BALB/c mice (Charles 15 
River Laboratories, Wilmington, MA) and Rag1-/- mice (BALB/c background, Jackson 16 
Laboratories, Bar Harbor, ME). CXCL13 or CCL21 were neutralised by i.v. injection of 17 
0.5ug goat antibodies (R&D Systems, Minneapolis, USA) starting on the first day after tumor 18 
establishment and repeated every 3d until the end of the experiment. ILCs were depleted by 19 
intraperitoneal injection of 0.25mg anti-CD90.2 (clone 30H12, BioXCell, West Lebanon, 20 
USA) starting on d3 after tumor establishment and repeated every 3d until the end of the 21 
experiment.  22 
Gene expression datasets: The KHP Cancer Biobank of the METABRIC dataset was 23 
profiled using the Illumina HT12 platform. Frozen tissue sections were subjected to 24 
histopathological review to assess the presence of invasive tumor and only samples with 25 
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>70% tumoral DNA were included. Samples were quantile normalised, and a ComBat 1 
BeadChip correction applied (n=234; 176 ER+ samples, 58 ER− samples). PAM50 subtype 2 
was assigned as in (11-13). 3 
Immunohistochemistry, Immunofluorescence and Image analysis:  60 fresh frozen tumor 4 
sections were randomly selected from the METABRIC patient cohort for ILC staining as 5 
described (14).  Confocal tile scan images were obtained using an LSM510 Metamicroscope 6 
(Carl Zeiss, UK). Image analysis for RORγt+ILC quantification was carried out using 7 
MacBiophototonics ImageJ software. Detailed immunohistochemistry protocols are described 8 
in Supplementary information. 9 
Cell Lines and culture conditions:  The mouse breast cancer cell line 4T1.2 (derived from a 10 
mammary carcinoma in a BALB/c mouse) (15) and human bone marrow derived MSC (HS-11 
5) were cultured in DMEM (Invitrogen, Carlsbad, CA) complete media. Extracellular matrix 12 
(ECM) invasion assays, based on the Boyden chamber principle, were carried out using 96-13 
well Cell Invasion Assay Kit (ECM555, Chemicon International, CA, USA) as per the 14 
manufacturers’ instructions.  To confirm identity, Short Tandem Repeat (STR) profiling was 15 
performed on all cell lines. 16 
ILC3 cell isolation and flow cytometry: For NKp46-ILC3 sorting experiments, splenocyte 17 
suspensions were prepared from BALB/c mice and cells stained with CD3, CD11c, B220R, 18 
CD127, CD90.2 and NKp46 and sorted by using a FACSAria. The NKp46-ILC3 were 19 
identified as CD3-CD11c-B220-CD127+CD90.2+NKp46- cells.  Purity was confirmed at 20 
>90%.  To extract intratumoural ILC3, tumors were minced and incubated with 21 
collagenase/hyaluronidase at 37°C for 60min; and passed through a filter to form a single cell 22 
suspension.  Cells were stained as per sorting experiments. Flow cytometry reference beads 23 
(PeakFlow blue; Invitrogen) were added to the samples before analysis for quantification of 24 
cells in each tumor. The absolute number of cells/mg of tumor was calculated using the 25 
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formula: Density of x cells = (number of beads added to each sample multiplied by count of x 1 
cells/count of beads)/tumour weight. For multi-photon experiments, 5–6×104 sorted NKp46-2 
ILC3 were injected (i.v) into tumor-bearing mice on the same day. Immune cell populations 3 
from tumors and DLN from mice after treatment with either neutralising anti-CXCL13, anti-4 
CCL21 or IgG control (R&D Systems, Minneopolis, USA) were isolated as described above. 5 
Antibodies used are included in Supplementary Table S1.  6 
Time-lapse microscopy and image analysis:  Cells were cultured in DMEM complete 7 
medium supplemented with 25mM HEPES. For NKp46-ILC3-MSC co-culture experiments, 8 
MSC were grown in 9.4×10.7 mm ibidiTM 8-well-slide chambers. Image acquisition was 9 
performed using an Olympus IX71 inverted microscope housed within an environment 10 
chamber maintained at 37°C. Sequential phase contrast images were captured every 10-11 
minutes for a total of 10h. NKp46-ILC3-MSC clustering was measured as described in 12 
Supplementary Information. 13 
ELISA: Tumors were snap frozen and lysed by homogenisation in 100mM Tris pH 7.5, 14 
150mM NaCl, 1mM EGTA, 1mM EDTA, 1% (v/v) Triton-X-100 and 0.5% (w/v) sodium 15 
deoxycholate. ELISAs were performed using DuoSet kits (R&D Systems, Minneopolis, 16 
USA). 17 
siRNA knockdown:  MSC were cultured overnight in 6-well plates to 30% confluency. Cells 18 
were transfected with RNAimax in serum free OptiMEM and siRNAs at 20nM. Details of the 19 
siRNA used are in Supplementary Table S2. 20 
Surgical window and Multi-photon Imaging:  Mammary Imaging Window (MIW) surgery 21 
was performed 10d after injection of 1×106 4T1.2 cells into the mammary fat-pad as 22 
described (16). For multi-photon experiments, 1×106 MSC  (control or knock-down) 23 
followed 24h later by 5×104 sorted NKp46-ILC3 cells were i.v. injected into mice. 24h later 24 
mice were placed in a microscope-attached imaging box kept at 32°C and imaged for a 25 
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maximum period of 3h/day for 3 consecutive days. Image processing and image 1 
reconstructions were done using MacBiophototonics ImageJ software.  2 
Statistics:  Permutation tests for small samples with multiple ties were performed using the 3 
“coin” package in R-2.13.0 (17). Predictive value of ILC score for high LN burden was 4 
determined using Cox’s multivariate proportional hazards model. GraphPad was used for 5 
other data analysis. P values  <0.05 were considered significant.  6 
 7 
Results 8 
 9 
CCL21-mediated recruitment of NKp46-ILC3 to tumors in a mouse model of triple 10 
negative breast cancer 11 
To investigate whether ILC3s are recruited into a TME, we used a mouse model of triple 12 
negative breast cancer (TNBC) with 4T1.2 cells in BALB/c mice that develop metastatic 13 
disease via lymphatics (Figure 1A) (18). Upon tumor induction, the number of NKp46-ILC3 14 
(19) were determined at different times in tumors, draining LN (DLN) and non-draining LN 15 
(NDLN) (Figure 1A,B). FACS and immunoflourescence staining for CCR6, RORγt, and CD4 16 
further confirmed the gated cells to be ILC3 (Supplementary Figure S1).  The number of 17 
NKp46-ILC3 cells in tumors peaked at d14 (d10 vs. d14 P=0.0019, unpaired t-test), while the 18 
number in DLN peaked later, at d18 (d10 vs. d18, P=0.0041 unpaired t-test) (Figure 1B). 19 
NKp46-ILC3 cell density within the NDLN did not change significantly, acting as an internal 20 
control.  Confocal imaging of primary tumours and DLNs taken at d14 and d21 respectively, 21 
for markers discriminatory for RORγt+ILC3 (defined as RORγt+CD127+CD3-) as previously 22 
published (20) confirmed the presence within our mouse model (Figure 1C and 1D).    In 23 
contrast to the temporal pattern of NKp46-ILC3 infiltration (Figure 1B), absolute numbers of 24 
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CD3+T cells (Figure 1E) and CD19+B cells (Figure 1F) decreased in tumors over time, while 1 
the number of T and B cells in the DLN continued to increase until d24. 2 
CXCL13 has an essential role in ILC3 function (5) and lymphoid structures resembling the 3 
LN paracortex develop in tumors expressing high levels of CCL21 (21). Therefore, we 4 
investigated whether either of these chemokines could play a role in the recruitment of 5 
NKp46-ILC3 cells to tumors in our model. We confirmed that tumor NKp46-ILC3 express 6 
both CCR7 and CXCR5, and are thus capable of responding to CCL21 and CXCL13, 7 
respectively (Figure 1G). We then analysed the levels of CCL21 and CXCL13 present in 8 
primary tumors and serum at various times after tumor establishment. CCL21 levels peaked 9 
in both the tumor and serum at d12, before declining rapidly (Figure 1H). CXCL13 in the 10 
tumor also peaked early (d10-12),  but levels in serum lagged behind, peaking at d14. In 11 
contrast to CCL21, CXCL13 oscillated, with tumor CXCL13 beginning to rise again at d20, 12 
and serum CXCL13 concentration increasing at d24 (Figure 1I). 13 
To examine the effect of CCL21 or CXCL13 blockade on NKp46-ILC3s recruitment to 14 
tumors in vivo, tumor-bearing mice were treated with control or neutralizing anti-CXCL13 15 
and anti-CCL21 antibodies, starting one day after tumor cell implantation and repeated every 16 
3 days. Tumors were analysed for NKp46-ILC3 at d14, a time-point at which maximum 17 
number of these cells had previously been shown to be present in the tumors (Figure 1B). 18 
When compared with isotype controls, anti-CCL21, but not anti-CXCL13 neutralizing 19 
antibodies, significantly reduced NKp46-ILC3s recruitment to the primary tumor (Figure 1J).  20 
CXCL13 is required for clustering of NKp46-ILC3 and MSC 21 
During embryogenesis clustering of NKp46-ILC3s and production of CXCL13 and CCL21 22 
by activated lymphoid tissue organizer cells (LTo, closely linked to stromal cells of 23 
mesenchymal origin (22)) are responsible for initiating a feedback loop with further NKp46-24 
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ILC3 recruitment and subsequent amplification of LT-receptor  signaling (23).  Given the 1 
lineage relationship between MSCs, which exhibit a marked tropism for tumors (24), and 2 
LTo cells that are known to interact with ILC3s, we hypothesized that ILC3 interaction with 3 
CXCL13-producing stromal cells may modulate the chemokine profile of the TME. Within 4 
our in-vitro model, MSCs secrete high concentrations of CCL21 and CXCL13 chemokines 5 
(Supplementary Figure S2).  6 
Time-lapse microscopy demonstrated NKp46-ILC3-MSC clustering (Figure 2A, upper panel 7 
and Video S1), with cells remaining closely associated for as long as 7h (Figure 2A, red 8 
arrow in lower panel and Video S2).  There was no effect on proliferation of ILC3 on contact 9 
or co-culture with MSCs (Supplementary Figure S3A).  We quantified cell clustering of 10 
NKp46-ILC3-MSC (Figure 2B) and  investigated how knockdown of CXCL13 and CCL21 in 11 
MSC (Supplementary Figure S3B and C) affected this clustering rate. Transient siRNA-12 
knockdown of CXCL13, but not of CCL21, resulted in a decrease of NKp46-ILC3-MSC 13 
clustering around (P<0.0001, unpaired t-test) (Figure 2C). CXCL13-mediated clustering may 14 
be synergistic with the initial CCL21-mediated recruitment of NKp46-ILC3 into the primary 15 
tumor, since the CCL21-recruited NKp46-ILC3 are required to promote significant CXCL13 16 
production by interaction with MSC. 17 
Next, we used an intravital mammary window (MIW) with multi-photon imaging to assess 18 
NKp46-ILC3-MSC interaction in vivo  (16). These visualisation experiments were conducted 19 
to demonstrate how the fluorescent MSC (which are allogenic and therefore could have a 20 
finite half-life once injected in vivo) may interact with ILC in the relatively short term and 21 
whether this interaction is CXCL13 dependent. 4T1.2 cells were injected into the mammary 22 
fat pad and a MIW placed over the tumor 10d after inoculation (Figure 2Di). Tumor-bearing 23 
mice were treated with either neutralizing anti-CXCL13 or isotype antibody (as described for 24 
Figure 1H). Fluorescently-labeled MSCs and NKp46-ILC3 were i.v. injected 48 or 24h prior 25 
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to imaging, respectively (Figure 2Dii). In control antibody-treated mice, NKp46-ILC3 were 1 
clustered and in close proximity to MSC. However, in mice injected with neutralizing anti-2 
CXCL13 antibody, NKp46-ILC3 and MSC were not close with each other (P<0.0001, 3 
unpaired t-test, Figure 2E, F). These in vivo imaging results support the in vitro observation 4 
that NKp46-ILC3-MSC clustering is CXCL13-dependent.  5 
 6 
CCL21, CXCL13 and NKp46-ILC3 cells promote metastasis of tumor cells to DLN 7 
To test the hypothesis that CCL21 and CXCL13 might play a role in promoting metastasis of 8 
tumor cells to  LN, we treated 4T1.2 tumor-bearing mice with neutralising antibodies against 9 
CCL21 or CXCL13, or with an antibody to deplete NKp46-ILC3 and examined the DLN for 10 
evidence of metastasis. 11 
In vivo, neither anti-CXCL13 nor anti-CCL21 treatments affected tumour growth (Figure 12 
3A). The weight of the DLNs were signficantly reduced in both cohorts (anti-CXCL13 13 
P=0.0156; and anti-CCL21 P=0.0017 one-way ANOVA) compared to the control cohort 14 
(Figure 3B).  Immunohistochemical analysis of DLN for tumor load with anti-pancytokeratin  15 
revealed fewer tumor foci within the DLN of  mice treated with anti-CXCL13 or anti-CCL21 16 
compared with control antibody-treated mice (Figure 3C). Measurements of the total surface 17 
area of of tumor foci (μm2) demonstrated a significant decrease in the tumor load in the DLN 18 
of mice treated with anti-CXCL13 or anti-CCL21 (P<0.05 one-way ANOVA; Figure 3C and 19 
3D). 20 
Given the involvement of CXCL13 and CCL21 in B- and T-cell homeostasis (2), we assessed 21 
the effect of anti-CXCL13 and anti-CCL21 blockade on LN metastasis in Rag1-/- mice which 22 
lack B and T cells. Rag1-/- mice have much smaller lymph nodes, these lymph nodes samples 23 
were therefore formalin fixed to help preserve the morphology better.  We report a decrease 24 
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in the number of pan-cytokeratin positive tumour cells in DLN of tumor-bearing Rag1-/- mice 1 
treated with blocking anti-CCL21 or anti-CXCL13 (anti-CXCL13 P=0.004; anti-CCL21 2 
P=0.005) (Figure 3E & 3F).  These results suggest that T and B cells are not involved in the 3 
CXCL13 and CCL21 dependent tumor cell migration into LNs. 4 
To strengthen the link between ILC and chemokines in LN metastasis we depleted ILCs  with 5 
anti-CD90.2, as previously described (25) (Figure 3G). It is noteworthy that anti-CD90.2 6 
does not specifically depletes ILC3 and is also able to deplete T cells. Therefore these 7 
experiments were also carried out  in Rag1-/- mice. We found a significant decrease in the 8 
tumor burden in the DLN of mice treated with anti-CD90.2 (P=0.04 Mann Whitney test 9 
Figure 3H). Therefore, CCL21, CXCL13 and ILCs themselves, and no B or T cells, all 10 
promote metastasis of breast cancer cells to the DLN. 11 
 12 
CXCL13 induces RANK/RANKL signalling to promote tumour cell invasion  13 
As our in vivo results suggested an inhibitory effect of CXCL13 or CCL21 blockade on 4T1.2 14 
cell invasion into the DLN, we used extracellular matrix (ECM) invasion assay, to directly 15 
investigate the effects of increasing concentrations of CXCL13 and CCL21 on tumour cell 16 
invasion. EGF stimulation of 4T1.2 and NIH3T3 served as positive and negative controls 17 
respectively. Recombinant CXCL13 or CCL21 did not significantly increase the invasion of 18 
4T1.2 cells at concentrations between 10-100ng/ml (Figure 4A). 19 
During LN development, the interaction of NKp46-ILC3-MSC stimulates RANKL 20 
production by MSC, and RANKL signals back to the NKp46-ILC3 establishing a positive 21 
feedback (26). CXCL13 has recently been shown to promote RANKL expression in stromal 22 
cells in oral squamous cell carcinoma (27); and RANK signaling in several breast cancer cell 23 
lines induces epithelial-mesenchymal transition, promoting cell migration and invasion (28). 24 
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To test the relationship between CXCL13 and RANK signaling in vitro; we first confirmed, 1 
as shown previously (27), that whilst 4T.12 cells expressed RANK receptor in vitro (Figure 2 
4B), but were not themselves the source of RANKL (Figure 4C).  Levels of over 200pg/ml of 3 
RANKL were observed in MSC conditioned media, supporting the hypothesis that the source 4 
of RANKL within the tumour is likely to be stromal (Figure 4C). Stimulation with CXCL13, 5 
but not CCL21, increased the expression of RANKL in MSC (paired t-test 50ng/ml vs 6 
control: P<0.01; Figure 4D & 4E).  We also confirmed that MSCs expressed CXCR5 as 7 
suggested by the above experiment (Supplementary Figure S4).  We next investigated if 8 
increasing concentrations of RANKL would increase 4T1.2 cells invasion. Addition of 9 
RANKL to 4T1.2 (between 10-100ng/ml) was observed to significantly increase the ability of 10 
the tumour cells to invade through the matrix (Figure 4F).   11 
To investigate the relationship between CXCL13 and RANKL expression in vivo, we 12 
analysed the changes in the levels of RANKL in the sera of 4T1.2 tumor-bearing mice at a 13 
number of timepoints after tumor establishment.  RANKL levels peaked at d18 (P<0.0001, 14 
unpaired t-test; Figure 4G), approximately 4d after the first serum peak in CXCL13 (Figure 15 
1H). In mice treated with anti-CXCL13, levels of RANKL at d14 were significantly reduced 16 
(P<0.001 unpaired t-test; Figure 4H), in support of the idea that CXCL13 drives RANKL 17 
production in vivo. A significant reduction in RANKL was also observed in anti-CCL21 18 
treated mice (P<0.001 unpaired t-test; Figure 4H).  19 
These findings led us to hypothesise that RANKL, like CCL21 and CXCL13, might promote 20 
metastasis of tumor cells to DLN. Treatment with anti-RANKL neutralizing antibody did not 21 
affect the growth of the primary tumor (Figure 4I). Immunohistochemical analysis of  DLN 22 
for tumor load revealed no metastasis in majority of antibody-treated mice (n = 5/7) and the 23 
mean area of tumor metastasis was lower in the antibody-treated mice than the controls 24 
(P<0.01, unpaired t-test; Figure 4J). RANKL blockade using a neutralising antibody did not 25 
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significantly affect the recruitment of NKp46-ILC3 into the primary tumors but the numbers 1 
in DLN were significantly lower, compared to the controls (P<0.05, one-way ANOVA; 2 
Figure 4K). 3 
 4 
RORγt+ILC and their associated chemokines are present in the human breast cancer 5 
TME 6 
We further analysed the gene expression of RORγt+ILC3-associated/lymphoid chemokines 7 
CXCL13, CCL19, and CCL21 and their receptors, CXCR5 and CCR7, in a subset of 234 8 
samples of breast cancer from the Molecular Taxonomy of Breast Cancer International 9 
Consortium (METABRIC) (29) (see Supplementary Table S3 for patient characteristics). 10 
Unsupervised hierarchical cluster analysis of the transcriptional profile in these samples 11 
revealed that this cohort could be categorized based on their expression of RORγt+ILC3-12 
associated/lymphoid chemokines and their receptors (Figure 5A). “Basal-like” breast cancers 13 
(PAM50 intrinsic subtype assignments (30)) presented high expression of these genes (31/53 14 
basal-like tumors lie in the top-branch cluster, n=89; P=0.0007, two-tailed Fisher's exact test) 15 
(Figure 5A). Further cross validation of these results was seen in 4-independent breast cancer 16 
datasets (Supplementary Figure S5). RORγt+ILC3-associated/lymphoid chemokine and their 17 
receptor genes were highly specific (no association with other lymphoid chemokine genes, 18 
such as the ligand-receptor pair CCL20-CCR6, which attract immature DC, effector/memory 19 
T-cells and B-cells) and showed significant internal pair-wise correlation (P<104, Figure 5B).  20 
We next stained frozen primary tumor sections for markers for RORγt+ILC3 (defined as 21 
RORγt+CD127+CD3-), as we previously published (20).  RORγt+ILC3 were present in 22 
approximately half of the sections examined (Figure 5C, 5D). These cells were in proximity 23 
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to CD3+T cells (Figure 5C) and found within TLS, as previously defined (31) 1 
(Supplementary Figure S6). We hypothesized that tumors with higher levels of RORγt+ILC3-2 
associated chemokines would have a higher number of RORγt+ILC3.  To test this, we 3 
performed a blinded study in primary breast cancer sections (total patients n=59). The 4 
number of RORγt+CD127+CD3- cells/mm2 (of total area/section) varied considerably from 5 
case to case (range 0–56/mm2) (Figure 5D) but patients with high tumor ILC3 counts were 6 
also likely to have a high gene expression score for the ILC3-associated chemokines (Figure 7 
5D; P<0.001, Spearman correlation permutation test). 8 
We next assessed the correlation of CXCL13 and CCL21 protein and gene expression levels 9 
with ILC3 scores. Fifty-nine cases with known ILC3 scores were stained for CXCL13 or 10 
CCL21 expression. For CXCL13 only stromal cells stained for this chemokine (Figure 5Ei).  11 
In contrast, CCL21 staining was positive for both tumoral and stromal cells.  We quantified 12 
the relationship between ILC3 and stromal CXCL13/CCL21 staining. ILC3 presence 13 
correlated positively with CXCL13 staining but not with stromal CCL21 (Figure 5Eii). These 14 
additional data strenghten our pre-clinical data (Figure 2), with CXCL13 up-regulation in 15 
stromal cells as a secondary event to the recruitment of ILC3 to the primary tumour. 16 
 17 
Tumoral RORγt+ILC3 cell density correlates with lymphatic tumor cell invasion and 18 
DLN metastasis within basal-like and HER2-enriched breast cancer 19 
We next stained tumor sections for the lymphatic endothelial cell marker, podoplanin, and 20 
evaluated  sections for evidence of tumor cell invasion into lymphatics (Figure 6Ai). We 21 
considered lymphatic invasion to have occurred if at least one tumor cell cluster was clearly 22 
visible in the lymphatic vascular space (red arrow in Figure 6Ai).  RORγt+ILC3 were present 23 
in 82% (14/17) of tumor samples with lymphatic tumor cell invasion but only in 27% (8/30)  24 
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of samples without lymphatic tumor cell invasion. Similarly, 73% (22/30) of samples without 1 
lymphatic tumor cell invasion had no RORγt+ILC3 present in the tumor, whereas only 17% 2 
(3/17) of samples without RORγt+ILC3 cells displayed lymphatic invasion (Figure 6ii; 3 
P<0.003, Fisher's exact test). We did not find an association between lymphatic invasion and 4 
CD3+T cells or with CD3+CD127+RORγt+ (most likely representing TH17 cells), 5 
strengthening the specificity of the correlation between RORγt+ILC3 cells and lymphatic 6 
invasion (Table 2).   We next investigated if the association between RORγt+ILC3 counts and 7 
lymphatic invasion translated into a high LN tumour burden (i.e. four or more metastatic LNs 8 
at surgical resection) within our dataset.  In basal-like breast cancer raised RORγt+ILC3 9 
counts were found to also correlate with a higher burden of LN metastases (P=0.02, 10 
permutation-based Mann–Whitney; Figure 6B).  Given our in vitro and in vivo findings, we 11 
investigated whether LN burden was related to gene expression of CCL21 and CXCL13 in 12 
the primary tumor. We found that in basal-like breast cancers a high LN tumor burden was 13 
associated with significantly increased levels of CCL21 (P=0.0043; LN positive, 4+ vs. 0; 14 
two-tailed Mann–Whitney; Figure 6C). Although CXCL13 levels were also increased in 15 
patients suffering from a high LN burden, this association was not significant (P=0.15; Figure 16 
6D). These correlations were not statistically significant in other breast cancer subtypes 17 
(HER2+ve or Luminal A/B), suggesting that the proposed mechanisms may only operate in 18 
specific breast cancer subtypes. In a multivariate (Cox’s) proportional hazards model and 19 
taking basal-like and HER2-enriched tumors together, the RORγt+ILC3 score achieved 84% 20 
prediction accuracy for high LN burden: higher than traditional clinicopathological 21 
parameters (e.g. grade, tumor size, receptor status; Figure 6E). 22 
 23 
 24 
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Discussion 1 
Recent years have seen a growing appreciation of the pleiotropic nature of the TME (32).  2 
The importance of ILC3s in normal lymphoid organogenesis has been accepted for long time 3 
but their role in the TME has only recently begun to be investigated. Work by Shields et al 4 
described, in a murine model of melanoma, a mechanism by which CCL21-expressing 5 
tumors recruit ILC3 cells, which transform the TME contributing to a tolerant milieu that 6 
promotes immune evasion (21). Study by Eisenring et al showed that RORγt+ILCs, are 7 
required for IL-12 to exert its anti-tumor activity (33). Similarly, a protective function of 8 
NKp46+ILC3 (distinct from the NKp46-ILC3) has been reported in lung cancers (34).  These 9 
findings are not necessarily at odds, since whether ILC3s promote or prevent cancer 10 
progression is likely to depend on the type of cancer and whether they recruit immune cells 11 
into a tolerogenic (21) or inflammatory (33) microenvironment. We report the presence of 12 
RORγt+ILC3 in human breast cancers and that they have a previously unrecognized function 13 
in facilitating tumor invasion into the lymphatic system through modulation of the local 14 
lymphoid chemokine milieu. We show that ILC3 recruitment into a TNBC tumor model is 15 
CCL21-dependent, whilst CXCL13 regulates their clustering with stromal cells (see Figure 16 
7).  17 
The CCL21/CCR7 axis plays a role in the progression of different malignancies (35, 36). 18 
These studies focus on the direct effects of CCL21 on CCR7-expressing tumor cells, rather 19 
than on how CCL21 may modify the TME. We show that CCL21 is expressed both in 20 
primary human breast cancers and in a mouse model of TNBC. In the mouse model, the peak 21 
of CCL21 expression in tumors was closely followed by ILC3 recruitment, an association we 22 
show to be causal through its prevention by CCL21 blockade, consistent with the melanoma 23 
xenograft study correlating tumor expression of CCL21 and ILC3 cells recruitment (21). 24 
17 
 
CXCL13 was not required for ILC3 recruitment to tumors but was important for the 1 
induction of ILC3-MSC clustering and RANKL upregulation by MSC. MSC are recruited to 2 
tumors early in development via mechanisms reminiscent of those that operate in chronic 3 
wound healing (37, 38). Once activated, they secrete CXCL13, CCL21 and CCL19 and 4 
secrete lymphangiogenic factors such a VEGF-C (39). This interaction, in the TME, may 5 
promote neo-lymphangiogenesis, increasing the number of lymphatic vessels into which 6 
tumor cells are able to migrate and thus increasing opportunities for lymphatic metastases.  7 
In addition to its role in promoting clustering, CXCL13 stimulates increased RANKL 8 
production by MSC. This is likely to facilitate DLN metastasis by promoting epithelial-9 
mesenchymal transition in breast cancer cells, enhancing their ability to migrate and 10 
metastasize (28, 40). This explains the reduction in serum levels of RANKL observed in anti-11 
CXCL13 treated mice. ILC3 interaction with CXCL13-producing stromal cells may 12 
constitute a positive feedback, with CXCL13 reinforcing the ILC3-MSC interaction as shown 13 
in vitro and by intravital imaging.  These are likely to explain our observations that patients 14 
with tumor cell invasion into the lymphatics were more likely to have a higher RORγt+ILC3 15 
score compared to patients without lymphatic vessel invasion, as well as the significant 16 
association between RORγt+ILC3 counts and greater risk of an increased number of LN 17 
metastasis in basal-like breast cancer patients. 18 
CXCL13 is highly expressed in clinical samples from some breast cancer patients (41) but 19 
there is conflicting evidence on how it affects disease progression. While high CXCL13-20 
CXCR5 expression positively correlate with classical determinants of poor prognosis (41, 21 
42), it serves as a good prognostic marker within this high-risk subgroup of breast cancer 22 
patients (42-44). Within the TME, the role of immune cells and/or chemokines is particularly 23 
complex (45, 46).  Here, we report that, downstream of CCL21-mediated recruitment of 24 
18 
 
intra-tumoral ILC3, CXCL13 promotes lymphatic invasion of tumor cells via the RANK-1 
RANKL signalling pathway. However, CXCL13 is also a powerful chemoattractant for 2 
lymphocytes (47). This is in line with our finding that basal-like breast cancers, which 3 
frequently bear a prominent lymphocytic infiltrate, presented a high score for the lymphoid 4 
chemokine/chemokine receptor gene signature, and our data demonstrating a decreased 5 
number of tumor-infiltrating lymphocytes (TILS) in anti-CCL21 or anti-CXCL13-treated 6 
mice. Additionally, the presence of TILS and TLS are described as key prognostic and 7 
predictive markers for specific breast cancer subtypes (47-50). Therefore, the well-8 
established role of CXCL13 as a chemoattractant could explain why, in a subset of cases, it 9 
seems to play a protective role.  In our cohort of patients, CCL21 expression and 10 
RORγt+ILC3 presence in the primary tumor were associated with increased DLN metastasis 11 
in basal-like breast cancer, but not in HER2+ve or luminalA/B subtypes. It is noteworthy that 12 
these data may not translate into worse prognosis for patients and additional studies are 13 
required to fully understand the clinical significance of these findings. 14 
One important consideration for any future development of chemokine-based therapeutic 15 
interventions is the interplay between the CCL19-CCL21/CCR7 and CXCL13/CXCR5 axes 16 
within tumors. Both have been implicated as important drivers of leukocyte trafficking and 17 
lymphoid organogenesis in physiological situations (51). However, it is important to make a 18 
distinction between the two chemokines in the pathological context of the TME since 19 
CXCL13, but not CCL21, is required for ILC3-MSCs clustering, which we proposed here to 20 
be an important regulatory mechanism in tumor cell migration through RANKL production 21 
by MSC.  22 
In summary, we propose that, in our tumor model, ILC3 are recruited to the tumor by CCL21, 23 
have a pivotal role in facilitating lymphatic vessel invasion by tumor cells and they do this 24 
19 
 
via two CXCL13-mediated positive feedback loops. Further investigation into how ILC3, 1 
MSC, CCL21, CXCL13 and RANKL are co-ordinated to establish a network of interactions 2 
between the tumor cells and their microenvironment is required. 3 
 4 
  5 
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Figure Legends 1 
Figure 1:  CCL21 recruits NKp46-ILC3 to tumors in a model of TNBC 2 
A: Mice were inoculated subcutaneously with 106 4T1.2 cells on d0. Control and tumor-bearing mice 3 
were culled on d10,12,14,18,20,24.  FACS analysis for NKp46-ILC3, CD3+T and CD19+B cells in 4 
tumors, DLN and NDLN (n=3/day). B:  Absolute number of NKp46-ILC3 in DLN and NDLN and 5 
cell counts/mg of tumor. Confocal micrographs of (C) primary tumor and (D) DLN in BALB/c mice.  6 
Yellow arrows point to ILC3.  Scale bars=15μm. Absolute number of CD3+T cells (E) and CD19+B 7 
cells (F) in DLN and NDLN and cell counts/milligram of tumor.  G: CCR7 and CXCR5 expression 8 
by intratumoural ILC3, CD3+ and CD19+ cells. Levels of CCL21 (H) and CXCL13 (I) in tumors and 9 
serum at indicated time points. (n≥3/time point). J: NKp46-ILC3/mg of tumor at d14 after tumor cell 10 
implantation, treated with anti-CCL21, anti-CXCL13 or isotype control antibody (n≥3). Significance 11 
determined by one-way ANOVA and data represent means±SEM 12 
 13 
Figure 2: CXCL13 is required for clustering of NKp46-ILC3 and MSC in vitro and in vivo 14 
A: Time-lapse microscopy of sorted splenic ILC3 co-cultured with MSC. Scale bars: upper panel= 15 
50μm; lower panel=20μm. B:  Representative phase contrast (upper panels) and binary images (lower 16 
panel) used for the quantification of cell clustering. The graph summarises the change in mean area of 17 
the field occupied by cells. C: NKp46-ILC3 co-cultured with MSC transfected with siRNA targeting 18 
CCL21, CXCL13 or control vector. D: i) MIW was surgically implanted on top of the developing 19 
tumor. ii) Schematic representation of the experimental plan for multi-photon imaging of MSC-20 
NKp46-ILC3 cell interaction. E:  Representative images (n=15 fields analyzed).  Scale bar=10μm. F: 21 
Mean distances between the centre of imaged MSCs and NKp46-ILC3 are shown. Significance was 22 
determined using unpaired t-tests. 23 
  24 
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Figure 3: CCL21, CXCL13 and ILCs promote metastasis of tumor cells to DLN 1 
Tumour-bearing mice were treated with either anti-CCL21, anti-CXCL13 or isotype control 2 
antibodies. n=6 mice per treatment group. A: Tumour growth over time. B: Weight of inguinal DLN 3 
from mice at d21. C:  Immunohistochemistry (IHC) of DLN from tumour-bearing BALB/c mice at 4 
d21 using anti-pancytokeratin (brown). D: Quantification of the total area of metastasis per mm2 of 5 
sectional area within LN at d21. E: IHC of DLN from tumour-bearing Rag1-/- mice at d21 using anti-6 
pan-cytokeratin (brown).  Orange arrows highlight the pan-cytokeratin+ tumour cells.  F: 7 
Quantification of the total number of pan-cytokeratin+ tumour cells/mm2 of sectional area within LN 8 
at d21 (n≥3 per group).   G: FACS analysis for ILC in the DLN of isotype control and anti-CD90.2-9 
treated Rag1-/- mice at d14. Gating as in Figure 1A. H: Pan-cytokeratin IHC (brown) of DLN of 10 
tumour-bearing Rag1-/- mice to assess tumour load in ILC-depleted (anti-CD90.2-treated) and non-11 
depleted (isotype control-treated) mice at d21 (bilateral tumors in 3 mice per treatment group (n=6 per 12 
treatment group). The bar graphs show the total area of metastasis per mm2 of sectional area within 13 
LN. Scale Bar=100μm. Data represent means±SEM. 14 
Figure 4: CXCL13 induces RANK-RANK-L signaling  15 
A: Cell invasion assay with 4T1.2 cells (white bars) and NIH3T3 cells (black bars, non-invasive 16 
control).  B: Confocal micrograph showing cytoplasmic and membranous staining of RANK (red) in 17 
4T1.2 cells. DAPI-stained nuclei are shown in blue.  C: Supernatants from co-culture experiments of 18 
4T1.2 cells and MSCs were analysed after 48h to determine RANKL level by ELISA.  D:  RANKL 19 
expression in MSCs following stimulation by rCXCL13. Scale bar=50μm. E: RANKL concentration 20 
in MSC culture supernatants after stimulation with the indicated concentrations of rCXCL13 or 21 
rCCL21. Data represent means±SEM, paired t-test.  F: Cell invasion assay, as described in A, with 22 
4T1.2 stimulated with EGF and RANKL. Note: data on Fig 4A and 4F is the data from the same 23 
experiment.  G: RANKL serum concentrations were determined at the indicated time points after 24 
tumour inoculation. (n=3 mice/timepoint). H:  RANKL serum concentration at d14 in mice treated 25 
with neutralizing antibodies as indicated.  Data represent means±SEM, unpaired t-test. I:  Tumour-26 
26 
 
bearing mice treated with either anti-RANKL or isotype control antibodies. The change in tumor 1 
volume with time after inoculation of 4T1.2 cells into the mammary fat pad is shown. J: 2 
Quantification of the total area of metastasis/mm2 of sectional area in DLN of tumour-bearing mice 3 
treated with anti-RANKL or isotype control.  Inset: representative IHC using anti-pancytokeratin 4 
(brown) to assess tumor burden in the anti-RANKL-treated cohort. K:  Absolute cell counts of 5 
NKp46-ILC3/milligram of tumour and within DLN from tumour-bearing mice treated with anti-6 
RANKL or isotype control antibody until d21. n≥3 mice/treatment group. (One-way ANOVA. Data 7 
represent means±SEM, unpaired t-test).   8 
Figure 5. RORγt+ILC3 and their associated chemokines in the human breast cancer TME. 9 
A: Hierarchical clustering of the expression of genes encoding lymphoid-associated chemokines and 10 
receptors in the Guy’s METABRIC data set (n=234). Columns represent patient samples, with 11 
dendrogram coloured according to the top-level cut-off point (black/red). PAM50 intrinsic subtype 12 
assignments are displayed below and association was determined using a two-tailed Fisher’s exact 13 
test.  B: Significance of pair-wise gene expression correlations for genes encoding lymphoid-14 
associated chemokines and receptors. C: H&E staining and confocal micrographs of fresh frozen 15 
section of a primary human breast cancer. RORγt+ILC3 are defined as CD3-CD127+RORγt+. Scale 16 
bar=15μm. D:  Comparison of gene expression profiles and presence of RORγt+ILC3. The heatmap 17 
illustrates relative expression of genes encoding RORγt+ILC3-associated chemokines and receptors. 18 
Columns (samples, n=59) are ordered by increasing expression score and rows by hierarchical 19 
clustering. The ranks of ILC3 counts (cells/mm2) are depicted below, ordered from lowest to highest. 20 
E: i) IHC analysis for CXCL13 and CCL21 in human breast tumour samples.  ii) Associations 21 
between stromal staining for CXCL13 or CCL21 and the presence/absence of RORγt+ILC3. The 22 
association of these two cytokines and ILC3 was determined using Fisher’s exact test.  23 
Figure 6:  Association of RORγt+ILC3 and lymphatic invasion within the TME 24 
A: i) IHC staining with lymphatic marker, podoplanin (brown) in primary human breast cancer tissue, 25 
cell nuclei are stained blue. Sections were examined for presence or absence of tumor cell invasion 26 
27 
 
into lymphatics (red arrow) Scale bar=100μm. ii) Lymphatic invasion is associated with the presence 1 
of RORγt+ILC3. The association between numbers of RORγt+ILC3, CD3+T cells or 2 
CD3+CD127+RORγt+ cells with lymphatic invasion was determined using Fisher’s exact test. CD3 3 
low was defined as <100cells/mm2, CD3 high as >100cells/mm2.   B: Correlation between ILC3 count 4 
and the presence of lymphatic metastasis.  (Mann Whitney-U-Test, is shown above the boxplots).  5 
Correlation between CCL21 (C) and CXCL13 (D) gene expression and lymphatic metastasis in the 6 
METABRIC dataset. Median-centred gene expression values are shown (arbitrary units). E: 7 
Prediction accuracy for LN burden amongst Basal/HER2-enriched tumours. Average validation 8 
accuracy is shown (red diamonds). Baseline accuracy using assignment of all values to the largest 9 
class is shown for comparison (grey). RORγt+ILC3/mm2 achieves prediction accuracy of 84% using 10 
median threshold of 11.6/mm2. 11 
Figure 7: In a model of triple negative breast cancer, we report on the CCL21-mediated recruitment 12 
of ILC3 to tumors where they stimulate stromal cells to produce CXCL13. CXCL13 feeds back to 13 
promote further interactions between ILC3 and stromal cells leading to production of RANKL, which 14 
enhances tumor cell motility resulting in lymph node metastases.  15 
 16 
 17 







